



The Rapid Response Partnership Vehicle Consortium Awards an Additional Project for its Biothreat Diagnostics Initiative

Aptitude Medical Systems, Inc. was awarded approximately \$9 million to further advance Ebola virus and Marburg virus testing options

Summerville, SC (July 17, 2025) — The Rapid Response Partnership Vehicle (RRPV) consortium has awarded \$9 million to [Aptitude Medical Systems, Inc.](#) (Aptitude) for development of a portable, pocket-sized, rapid, molecular, multiplex biothreat diagnostic for detection and differentiation of Ebola virus and Marburg virus species infections in remote and more traditional point-of-care settings.

“This project aims to advance the development and production of a diagnostic tool targeting high priority biothreats,” said Dr. Mike Stebbins, senior vice president for the medical and threat countermeasures division at Advanced Technology International. “Our RRPV team is proud to contribute to strengthening national health security by accelerating the development of technologies to combat emerging infectious diseases.”

The project aims to build on Aptitude’s current respiratory tests on the Metrix Platform by expanding to detect and differentiate Ebola virus and Marburg virus species, including filovirus detection, from whole blood samples. Currently, the Metrix Platform offers two tests that detect COVID-19 and COVID/Flu. These tests feature low-cost kits, along with a pocket-sized reusable reader.

Aptitude will also evaluate additional suppliers, including domestic sources, to increase supply chain resilience, capability for rapid scaling, and cost reduction.

The project is part of the RRPV’s [diagnostics rapid response initiative](#), a biothreat diagnostics program that supports the development of diagnostics assays, instruments, and devices to diagnose diseases caused by biothreats.

Funding for the project comes from the [Biomedical Advanced Research and Development Authority](#) (BARDA), part of the Administration for Strategic Preparedness and Response, within the U.S. Department of Health and Human Services, which oversees the RRPV under Other Transaction Authority agreement 75A50123D00005.

To learn more about the award, visit rrpv.org/awards/.



About the Rapid Response Partnership Vehicle

The Rapid Response Partnership Vehicle (RRPV) is a 10-year, multi-purpose program designed to support medical countermeasures, such as vaccines, therapeutics, and medical technology products from early-stage development through advanced development, procurement, sustainment, and commercialization, including manufacturing infrastructure development. The RRPV is managed by [Advanced Technology International](#). To learn more, visit [RRPV.org](https://rrpv.org), and stay connected by following @RRPV on LinkedIn and X.